United Therapeutics has halted a late stage trial for its pulmonary arterial hypertension candidate after the drug failed to achieve the study's primary endpoint.
The stage III BEAT clinical study of esuberaprost tablets in patients suffering from PAH did not meet its goal of delayed time to first clinical worsening event.
The Maryland-based biotech had been testing the project in combination with its inhaled treprostinil solution, Tyvaso. The company will terminate development as a result of the trial fail.
Read the press release.